Literature DB >> 10929070

Biological function of CD40 on human endothelial cells: costimulation with CD40 ligand and interleukin-4 selectively induces expression of vascular cell adhesion molecule-1 and P-selectin resulting in preferential adhesion of lymphocytes.

K Kotowicz1, G L Dixon, N J Klein, M J Peters, R E Callard.   

Abstract

The expression of adhesion molecules on vascular endothelial cells determines the pattern of migration and extravasation of leucocytes in inflammation and immunity. Here we show that costimulation with CD40 ligand (CD40L) and interleukin (IL)-4 (or IL-13) gives rise to a unique pattern of adhesion molecule expression by human umbilical vein endothelial cells (HUVEC). CD40 ligation alone enhanced expression of vascular cell adhesion molecule-1 (VCAM-1), intracellular adhesion molecule-1 (ICAM-1) and E-selectin whereas IL-4 and IL-13 increased expression of VCAM-1 and P-selectin but not ICAM-1 or E-selectin. When IL-4 and CD40L were combined there was an additional increase of both VCAM-1 and P-selectin, but ICAM-1 and E-selectin were both inhibited. The combined effects of IL-4 and CD40L signalling were not the result of altered response kinetics, enhanced sensitivity of the endothelium, or increased expression of CD40 or the IL-4 receptor. The rise in VCAM-1 expression induced by combined IL-4 and CD40L stimulation was slower and more sustained than with tumour necrosis factor-alpha (TNF-alpha) and occurred only on a subset (75-80%) of the endothelial cell population compared to 100% with TNF-alpha. Costimulation with IL-4 and CD40L increased adhesion of T cells and B cells above levels obtained with either signal alone, but decreased adhesion of neutrophils. Furthermore, CD40 and IL-4 synergistically increased IL-6 but decreased IL-8 production by HUVEC. These results show that interactions between IL-4 and CD40 on endothelial cells give rise to specific patterns of adhesion molecule expression and cytokine production that may have important implications for lymphocyte and neutrophil migration and function at sites of inflammation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10929070      PMCID: PMC2327040          DOI: 10.1046/j.1365-2567.2000.00061.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  41 in total

1.  IL-4 down-regulates IL-1 and TNF gene expression in human monocytes.

Authors:  R Essner; K Rhoades; W H McBride; D L Morton; J S Economou
Journal:  J Immunol       Date:  1989-06-01       Impact factor: 5.422

2.  PADGEM (GMP140) is a component of Weibel-Palade bodies of human endothelial cells.

Authors:  R Bonfanti; B C Furie; B Furie; D D Wagner
Journal:  Blood       Date:  1989-04       Impact factor: 22.113

3.  Rapid neutrophil adhesion to activated endothelium mediated by GMP-140.

Authors:  J G Geng; M P Bevilacqua; K L Moore; T M McIntyre; S M Prescott; J M Kim; G A Bliss; G A Zimmerman; R P McEver
Journal:  Nature       Date:  1990-02-22       Impact factor: 49.962

4.  Activation of human B lymphocytes through CD40 and interleukin 4.

Authors:  A Vallé; C E Zuber; T Defrance; O Djossou; M De Rie; J Banchereau
Journal:  Eur J Immunol       Date:  1989-08       Impact factor: 5.532

5.  PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes.

Authors:  E Larsen; A Celi; G E Gilbert; B C Furie; J K Erban; R Bonfanti; D D Wagner; B Furie
Journal:  Cell       Date:  1989-10-20       Impact factor: 41.582

6.  GMP-140, a platelet alpha-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies.

Authors:  R P McEver; J H Beckstead; K L Moore; L Marshall-Carlson; D F Bainton
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

7.  Two differently regulated nuclear factor kappaB activation pathways triggered by the cytoplasmic tail of CD40.

Authors:  N Tsukamoto; N Kobayashi; S Azuma; T Yamamoto; J Inoue
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

8.  Synergistic interaction between interleukin 4 and anti-Bp50 (CDw40) revealed in a novel B cell restimulation assay.

Authors:  J Gordon; M J Millsum; G R Guy; J A Ledbetter
Journal:  Eur J Immunol       Date:  1987-10       Impact factor: 5.532

9.  IL-4 increases human endothelial cell adhesiveness for T cells but not for neutrophils.

Authors:  M H Thornhill; U Kyan-Aung; D O Haskard
Journal:  J Immunol       Date:  1990-04-15       Impact factor: 5.422

10.  A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation.

Authors:  P E Stenberg; R P McEver; M A Shuman; Y V Jacques; D F Bainton
Journal:  J Cell Biol       Date:  1985-09       Impact factor: 10.539

View more
  19 in total

1.  Platelet and soluble CD40L in meningococcal sepsis.

Authors:  David P Inwald; Saul N Faust; Paula Lister; Mark J Peters; Michael Levin; Robert Heyderman; Nigel J Klein
Journal:  Intensive Care Med       Date:  2006-06-30       Impact factor: 17.440

2.  CD40-CD40 Ligand Pathway is a Major Component of Acute Neuroinflammation and Contributes to Long-term Cognitive Dysfunction after Sepsis.

Authors:  Monique Michels; Lucinéia Gainski Danieslki; Andriele Vieira; Drielly Florentino; Dhébora Dall'Igna; Letícia Galant; Beatriz Sonai; Francieli Vuolo; Franciele Mina; Bruna Pescador; Diogo Dominguini; Tatiana Barichello; João Quevedo; Felipe Dal-Pizzol; Fabrícia Petronilho
Journal:  Mol Med       Date:  2015-03-26       Impact factor: 6.354

3.  Chronic Chlamydia pneumoniae infection may promote coronary artery disease in humans through enhancing secretion of interleukin-4.

Authors:  R Clancy; Z Ren; G Pang; P Fletcher; C D'Este
Journal:  Clin Exp Immunol       Date:  2006-11       Impact factor: 4.330

4.  Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis.

Authors:  Dirk Lievens; Alma Zernecke; Tom Seijkens; Oliver Soehnlein; Linda Beckers; Imke C A Munnix; Erwin Wijnands; Pieter Goossens; Roger van Kruchten; Larissa Thevissen; Louis Boon; Richard A Flavell; Randolph J Noelle; Norbert Gerdes; Erik A Biessen; Mat J A P Daemen; Johan W M Heemskerk; Christian Weber; Esther Lutgens
Journal:  Blood       Date:  2010-08-12       Impact factor: 22.113

5.  Soluble adhesion molecules ICAM-1, VCAM-1, P-selectin in children with Helicobacter pylori infection.

Authors:  Elzbieta Maciorkowska; Maciej Kaczmarski; Anatol Panasiuk; Katarzyna Kondej-Muszynska; Andrzej Kemonai
Journal:  World J Gastroenterol       Date:  2005-11-21       Impact factor: 5.742

6.  Expression of CD40 identifies a unique pathogenic T cell population in type 1 diabetes.

Authors:  David H Wagner; Gisela Vaitaitis; Richard Sanderson; Michelle Poulin; Cathleen Dobbs; Kathryn Haskins
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

7.  CD40 ligand induces expression of vascular cell adhesion molecule 1 and E-selectin in orbital fibroblasts from patients with Graves' orbitopathy.

Authors:  Hao Wang; Li-Shuang Zhu; Jin-Wei Cheng; Ji-Ping Cai; You Li; Xiao-Ye Ma; Rui-Li Wei
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-01-11       Impact factor: 3.117

Review 8.  Immune Checkpoint Therapies and Atherosclerosis: Mechanisms and Clinical Implications: JACC State-of-the-Art Review.

Authors:  Jacqueline T Vuong; Ashley F Stein-Merlob; Arash Nayeri; Tamer Sallam; Tomas G Neilan; Eric H Yang
Journal:  J Am Coll Cardiol       Date:  2022-02-15       Impact factor: 24.094

9.  CD40/CD40L contributes to hypercholesterolemia-induced microvascular inflammation.

Authors:  Karen Y Stokes; Leshanna Calahan; Candiss M Hamric; Janice M Russell; D Neil Granger
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-12-26       Impact factor: 4.733

10.  Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions.

Authors:  Amrie C Grammer; Rebecca Slota; Randy Fischer; Hanan Gur; Hermann Girschick; Cheryl Yarboro; Gabor G Illei; Peter E Lipsky
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.